TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Roth Mkm

Roth Mkm assumed coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a report issued on Monday, MarketBeat reports. The brokerage issued a buy rating and a $11.00 target price on the stock.

TLSI has been the subject of a number of other research reports. Northland Securities began coverage on TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price for the company. Oppenheimer assumed coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They issued an “outperform” rating and a $10.00 target price for the company. Finally, Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, TriSalus Life Sciences presently has a consensus rating of “Buy” and an average target price of $12.25.

TriSalus Life Sciences Stock Performance

NASDAQ:TLSI opened at $4.01 on Monday. The firm has a market cap of $122.26 million, a P/E ratio of -1.80 and a beta of 0.49. TriSalus Life Sciences has a fifty-two week low of $3.32 and a fifty-two week high of $10.42. The firm has a 50-day simple moving average of $4.38 and a two-hundred day simple moving average of $5.85.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The company had revenue of $7.36 million for the quarter. On average, equities research analysts predict that TriSalus Life Sciences will post -1.5 EPS for the current year.

Insider Transactions at TriSalus Life Sciences

In related news, CEO Mary T. Szela bought 7,520 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were bought at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the transaction, the chief executive officer now owns 377,382 shares of the company’s stock, valued at approximately $1,962,386.40. This trade represents a 2.03 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 32.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TLSI. Highbridge Capital Management LLC purchased a new stake in TriSalus Life Sciences in the 2nd quarter worth approximately $1,184,000. Wolverine Asset Management LLC purchased a new stake in shares of TriSalus Life Sciences in the second quarter worth $240,000. Duquesne Family Office LLC increased its stake in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after purchasing an additional 110,966 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of TriSalus Life Sciences during the 3rd quarter valued at $66,000. Finally, MSD Partners L.P. purchased a new position in shares of TriSalus Life Sciences during the 3rd quarter valued at $184,000. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.